Comparison of 6 Cycles of Isatuximab with Lenalidomide, Bortezomib and Dexamethasone (I-Vrd) Versus 3 Cycles of I-VRd Followed by One Cycle of High-Dose Melphalan in Newly Diagnosed Low-Risk Multiple Myeloma. Protocol for a Multicenter, Prospective, Randomized, Phase II Clinical Trial (Elias-Trial)
Frontiers in Hematology（2024）
关键词
newly diagnosed multiple myeloma,clinical trial,high-dose melphalan,autologous stem cell transfusion,isatuximab,MRD
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要